Developer docs
API playgroundTry for free, no card

Search company profiles

Defymed

Full company profile

uuid00049yw

Namestring
Defymed
Legal namestring
Defymed SAS
Websiteurl
defymed.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Defymed SAS is a privately held French medical device company founded in 2011 as a spin-off of the Centre Européen d'Étude du Diabète (CeeD) in Strasbourg, developing implantable bio-artificial devices for therapeutic drug and cell delivery. The company operates two core proprietary products: MailPan®, a bio-artificial pancreas that encapsulates insulin-secreting cells within a patented semi-permeable membrane allowing glucose and insulin passage while blocking the recipient's immune system, enabling cell therapy without immunosuppressants; and ExOlin®, a fully implantable insulin delivery device designed to deliver insulin intraperitoneally via subcutaneous refill, targeting improved glycemic stability versus conventional subcutaneous administration. Both devices are Class III implantable medical devices certified under ISO 13485:2016 and progressing toward CE marking under MDR 2017/745 with TÜVSüd as notified body.

Defymed's business model is pre-commercial and rests on three pillars: (1) licensing MailPan and ExOlin to large medical device groups after regulatory approval, with royalties as the primary revenue stream; (2) service provision to external partners for in vitro and in vivo validation of cell-drug-device combinations using Defymed's R&D facilities and experimental models; and (3) public and private grant funding to advance the R&D pipeline. Indications under active exploration extend beyond Type 1 diabetes to hemophilia A/B, lysosomal diseases, Alzheimer's, pituitary diseases, cancer therapy, pain management, and obesity. Distribution is currently achieved through conference-led partnership development (IPITA, ISCT, EAHAD, ATTD, Cell & Gene Meeting on the Mesa, ESB) and academic collaborations with institutions including University of Oxford, LMU Munich, UCLouvain, and CHRU Strasbourg.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersStrasbourg, France
HQ citystring
Strasbourg
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
implantable medical devices, cell encapsulation therapy, bio-artificial pancreas, insulin delivery systems, diabetes treatment devices
Industry2 codes
PRIMARYHLAHAIAG
Insulin Pumps & Patch Pumps
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAHAC
Patch Pumps & Wearable Insulin Delivery
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Implantable Medical Devices
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Licensing
TypeLicensing Royalties
Description

Defymed plans to pursue commercial release through licensing to a large group specializing in medical devices after receiving regulatory approval (CE marking planned around 2023).

defymed.com
2Medical Device Development and Service Provision
TypeProfessional Services
Description

Full chain R&D facilities combining both in vitro and in vivo assays using well-established experimental models. Service provision for external partners seeking to validate combinations of cells and/or drugs with Defymed devices.

defymed.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1MailPan®
Description

Bio-artificial implantable pancreas device for cell encapsulation intended to regulate blood glucose levels in type 1 diabetes patients.

defymed.com
+1 more record
Core offering1 text field

Defymed develops and markets implantable bio-artificial medical devices for diverse therapeutic applications. Its two core products are MailPan®, a bio-artificial pancreas that encapsulates insulin-secreting cells within an immunoprotective semi-permeable membrane, and ExOlin®, a fully implantable insulin delivery device that enables physiological intraperitoneal insulin administration. Both are Class III soft-tissue implantable medical devices targeting type 1 diabetes and adjacent indications such as hemophilia, cancer therapy, and pain management.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Improved glycemic control with only 25.3% of diabetic men and 36.4% of diabetic women currently achieving proper blood sugar control (HbA1C <7%)
+2 more records
Product overview1 text field

Defymed develops and markets implantable bio-artificial medical devices for therapeutic applications, primarily focused on diabetes treatment. The portfolio consists of two core products: MailPan® (a bio-artificial pancreas for cell encapsulation therapy) and ExOlin® (a physiological insulin delivery device). Both are implantable medical devices targeting Type 1 diabetes patients to provide more effective and physiological treatment compared to conventional subcutaneous insulin administration.

Product and service3 records
1MailPan®
2ExOlin®
CategoryImplantable medical device (insulin delivery)
Description

Fully implantable insulin delivery device that makes insulin injections more efficient through intraperitoneal delivery via simple subcutaneous injection. Features a biocompatible, non-biodegradable membrane permeable to insulin but impermeable to receiver tissues, designed to improve glycemic stability and reduce chronic complications. Target users are type 1 diabetes patients requiring more physiologic insulin delivery.

3Service Provision (R&D validation services)
CategoryR&D / preclinical service
Description

Full-chain R&D services combining both in vitro and in vivo assays using established experimental models, offered to external partners that want to validate combinations of therapeutic cells and/or drugs with Defymed's MailPan® and ExOlin® devices.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
1DECAPES Consortium (ICPEES & Statice)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-09-01
Description

Defymed leads the DECAPES project alongside ICPEES (CNRS unit specializing in electrospinning) and Statice (medical device manufacturer). The project, funded by PIA and PSPC with €1.6M (€990K public aid), aims to develop a minimally invasive version of MailPan® using new ultraperformant electrospun membranes. Running from September 2021 for 3 years, it positions Defymed among world leaders in cell encapsulation.

defymed.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-02-01
Description

Strategic partnership for ENCAPSULIN project combining Defymed's MailPan® device with Kadimastem's insulin-secreting cells. Presented together at ATTD 2020 Technology Fair in Madrid.

3IRCAD-Strasbourg
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with IRCAD (Institute of Research against Digestive Cancers) for deLIVER project developing minimally invasive surgery (laparoscopy) for ExOlin® implantation at innovative drug delivery site.

defymed.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Participation in JDRF Fall Beta Cell Replacement Consortium, a global network of top researchers and industry leaders accelerating cell therapy and encapsulation for type 1 diabetes treatment.

Strategic tierCoreTypeTechnology or Integration
Description

Academic partnership with Oxford's Pancreatic Islet Transplant program and UK Islet Transplant Consortium for cell encapsulation research.

Strategic tierModerateTypeTechnology or Integration
Description

Academic partnership with LMU Munich's Institute for Molecular Animal Breeding and Biotechnology and Center for Innovative Medical Models.

7Université catholique de Louvain (UCLouvain)
Strategic tierModerateTypeTechnology or Integration
Description

Academic partnership with UCLouvain's experimental surgery laboratory and pancreatic islet transplantation research program.

defymed.com
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Medical device manufacturer providing design and manufacturing support for MailPan® and ExOlin® devices since Defymed's creation. Responsible for industrialization of electrospinning process in DECAPES project.

Strategic tierModerateTypeTechnology or Integration
Description

Partner in iNanoBIT project applying nanotechnologies for imaging of pancreatic islet cell transplants.

Strategic tierModerateTypeTechnology or Integration
Description

Partner in iNanoBIT project for development of optoacoustic imaging technologies.

11CHRU Strasbourg / University Hospitals of Strasbourg
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical collaboration with Prof. Nathalie Jeandidier (head of endocrinology and diabetology) for ExOlin® clinical trials. Cohort of ~10 patients selected for first clinical trial phase.

defymed.com
12Centre Européen Étude du Diabète (CeeD)
Strategic tierCoreTypeTechnology or Integration
Description

Defymed is a spin-off of CeeD which began work on bio-artificial pancreas in 1996. CeeD provides laboratory access and ongoing R&D collaboration.

defymed.com
13CTTM (Centre de Transfert de Technologie du Mans)
Strategic tierModerateTypeTechnology or Integration
Description

Technology transfer center providing expertise in biological/medical engineering and materials. Involved since early MailPan® development, contributing to biocompatible membrane performance improvements.

defymed.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Maker of the Omnipod 5 tubeless patch pump - the leading patch-style insulin delivery device on the market, competing for the same T1D patients and increasingly the benchmark for "wearable" insulin delivery that ExOlin must differentiate against.

TypeBroad incumbent
Description

Dominant incumbent insulin pump maker (MiniMed 780G closed-loop system) serving the same T1D patient population that Defymed targets with ExOlin - represents both the competitive benchmark and the most likely strategic licensee for ExOlin post-CE marking.

TypeBroad incumbent
Description

Established insulin pump manufacturer (t:slim X2 with Control-IQ closed loop) competing directly with any future ExOlin launch in the T1D market, and a credible strategic acquirer/licensee candidate given its pure-play diabetes focus.

TypeDirect peer
Description

Develops the Cell Pouch System, an implantable cell-therapy delivery platform for islet cells in T1D and other therapeutic cells - conceptually adjacent to Defymed's MailPan bio-artificial pancreas, both targeting immune-protected cell therapy without chronic immunosuppression.

5ViaCyte (acquired by Vertex Pharmaceuticals)
TypeDirect peer
Description

Direct competitor developing PEC-Direct (VC-02) encapsulated stem-cell-derived pancreatic progenitor implants for Type 1 diabetes - same encapsulated cell-therapy-for-T1D concept as Defymed's MailPan. Acquired by Vertex in 2022, accelerating the competitive timeline.

6Beta-O2 Technologies
TypeDirect peer
Description

Israeli company developing the βAir bio-artificial pancreas, an implantable macro-encapsulation device for allogeneic islet cells with oxygen supply - direct competing approach to Defymed's MailPan for T1D.

7Procyon Technologies
TypeEmerging player
Description

Early-stage company developing an oxygen-generating cell-encapsulation platform for diabetes (similar therapeutic thesis to MailPan) - competitor for the same encapsulation-for-T1D thesis and for the same licensing partners.

TypeEmerging player
Description

Israeli cell-therapy company developing IsletRx (insulin-secreting cells) - Defymed's named partner in the ENCAPSULIN project and a partial competitor since both pursue encapsulated cell therapy for T1D.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Defymed

Implantable Medical Devicesdefymed.com

What Defymed does

Defymed SAS is a privately held French medical device company founded in 2011 as a spin-off of the Centre Européen d'Étude du Diabète (CeeD) in Strasbourg, developing implantable bio-artificial devices for therapeutic drug and cell delivery. The company operates two core proprietary products: MailPan®, a bio-artificial pancreas that encapsulates insulin-secreting cells within a patented semi-permeable membrane allowing glucose and insulin passage while blocking the recipient's immune system, enabling cell therapy without immunosuppressants; and ExOlin®, a fully implantable insulin delivery device designed to deliver insulin intraperitoneally via subcutaneous refill, targeting improved glycemic stability versus conventional subcutaneous administration. Both devices are Class III implantable medical devices certified under ISO 13485:2016 and progressing toward CE marking under MDR 2017/745 with TÜVSüd as notified body.

Defymed's business model is pre-commercial and rests on three pillars: (1) licensing MailPan and ExOlin to large medical device groups after regulatory approval, with royalties as the primary revenue stream; (2) service provision to external partners for in vitro and in vivo validation of cell-drug-device combinations using Defymed's R&D facilities and experimental models; and (3) public and private grant funding to advance the R&D pipeline. Indications under active exploration extend beyond Type 1 diabetes to hemophilia A/B, lysosomal diseases, Alzheimer's, pituitary diseases, cancer therapy, pain management, and obesity. Distribution is currently achieved through conference-led partnership development (IPITA, ISCT, EAHAD, ATTD, Cell & Gene Meeting on the Mesa, ESB) and academic collaborations with institutions including University of Oxford, LMU Munich, UCLouvain, and CHRU Strasbourg.

Defymed firmographics

Firmographics
Name
Defymed
Legal name
Defymed SAS
Website
https://defymed.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Defymed industry classification

Industry
Product category
Implantable Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAIAG
Insulin Pumps & Patch Pumps
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAHAC
Patch Pumps & Wearable Insulin Delivery
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)

Keywords

  • Implantable medical devices
  • Cell encapsulation therapy
  • Bio-artificial pancreas
  • Insulin delivery systems
  • Diabetes treatment devices

Where Defymed is headquartered

Location

Headquarters

HQ city
Strasbourg
HQ country
France
HQ region
Europe

Offices2 records

Markets served

Defymed business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Medical Device Licensing: Defymed plans to pursue commercial release through licensing to a large group specializing in medical devices after receiving regulatory approval (CE marking planned around 2023).
  2. Medical Device Development and Service Provision: Full chain R&D facilities combining both in vitro and in vivo assays using well-established experimental models. Service provision for external partners seeking to validate combinations of cells and/or drugs with Defymed devices.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Defymed product offering

Product offering

Core offering

Defymed develops and markets implantable bio-artificial medical devices for diverse therapeutic applications. Its two core products are MailPan®, a bio-artificial pancreas that encapsulates insulin-secreting cells within an immunoprotective semi-permeable membrane, and ExOlin®, a fully implantable insulin delivery device that enables physiological intraperitoneal insulin administration. Both are Class III soft-tissue implantable medical devices targeting type 1 diabetes and adjacent indications such as hemophilia, cancer therapy, and pain management.

Product overview

Defymed develops and markets implantable bio-artificial medical devices for therapeutic applications, primarily focused on diabetes treatment. The portfolio consists of two core products: MailPan® (a bio-artificial pancreas for cell encapsulation therapy) and ExOlin® (a physiological insulin delivery device). Both are implantable medical devices targeting Type 1 diabetes patients to provide more effective and physiological treatment compared to conventional subcutaneous insulin administration.

Differentiator

Problem solved

Functional benefit

Brands

  • MailPan®: Bio-artificial implantable pancreas device for cell encapsulation intended to regulate blood glucose levels in type 1 diabetes patients.
  • ExOlin®

Products and services

  • MailPan®
  • ExOlin® Fully implantable insulin delivery device that makes insulin injections more efficient through intraperitoneal delivery via simple subcutaneous injection. Features a biocompatible, non-biodegradable membrane permeable to insulin but impermeable to receiver tissues, designed to improve glycemic stability and reduce chronic complications. Target users are type 1 diabetes patients requiring more physiologic insulin delivery.
  • Service Provision (R&D validation services) Full-chain R&D services combining both in vitro and in vivo assays using established experimental models, offered to external partners that want to validate combinations of therapeutic cells and/or drugs with Defymed's MailPan® and ExOlin® devices.

Quantifiable outcome

  • Improved glycemic control with only 25.3% of diabetic men and 36.4% of diabetic women currently achieving proper blood sugar control (HbA1C <7%)
  • +2 more outcomes

Companies that use Defymed

Customer profile

Segments3 records

Ideal customer profiles3 records

Defymed technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Defymed partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and moderate.

  • DECAPES Consortium (ICPEES & Statice)coreStrategic or Co-development Partner · 1 September 2021Defymed leads the DECAPES project alongside ICPEES (CNRS unit specializing in electrospinning) and Statice (medical device manufacturer). The project, funded by PIA and PSPC with €1.6M (€990K public aid), aims to develop a minimally invasive version of MailPan® using new ultraperformant electrospun membranes. Running from September 2021 for 3 years, it positions Defymed among world leaders in cell encapsulation.
  • KadimastemcoreStrategic or Co-development Partner · 1 February 2020Strategic partnership for ENCAPSULIN project combining Defymed's MailPan® device with Kadimastem's insulin-secreting cells. Presented together at ATTD 2020 Technology Fair in Madrid.
  • IRCAD-StrasbourgcoreStrategic or Co-development PartnerCollaboration with IRCAD (Institute of Research against Digestive Cancers) for deLIVER project developing minimally invasive surgery (laparoscopy) for ExOlin® implantation at innovative drug delivery site.
  • JDRFcoreStrategic or Co-development PartnerParticipation in JDRF Fall Beta Cell Replacement Consortium, a global network of top researchers and industry leaders accelerating cell therapy and encapsulation for type 1 diabetes treatment.
  • University of Oxford (Nuffield Department of Surgical Sciences)coreTechnology or IntegrationAcademic partnership with Oxford's Pancreatic Islet Transplant program and UK Islet Transplant Consortium for cell encapsulation research.
  • Ludwig-Maximilians-Universität München (LMU Munich)moderateTechnology or IntegrationAcademic partnership with LMU Munich's Institute for Molecular Animal Breeding and Biotechnology and Center for Innovative Medical Models.
  • Université catholique de Louvain (UCLouvain)moderateTechnology or IntegrationAcademic partnership with UCLouvain's experimental surgery laboratory and pancreatic islet transplantation research program.
  • STATICEcoreImplementation/ SI/ Consulting PartnerMedical device manufacturer providing design and manufacturing support for MailPan® and ExOlin® devices since Defymed's creation. Responsible for industrialization of electrospinning process in DECAPES project.
  • BioTalentum Ltd.moderateTechnology or IntegrationPartner in iNanoBIT project applying nanotechnologies for imaging of pancreatic islet cell transplants.
  • iThera MedicalmoderateTechnology or IntegrationPartner in iNanoBIT project for development of optoacoustic imaging technologies.
  • CHRU Strasbourg / University Hospitals of StrasbourgcoreStrategic or Co-development PartnerClinical collaboration with Prof. Nathalie Jeandidier (head of endocrinology and diabetology) for ExOlin® clinical trials. Cohort of ~10 patients selected for first clinical trial phase.
  • Centre Européen Étude du Diabète (CeeD)coreTechnology or IntegrationDefymed is a spin-off of CeeD which began work on bio-artificial pancreas in 1996. CeeD provides laboratory access and ongoing R&D collaboration.
  • CTTM (Centre de Transfert de Technologie du Mans)moderateTechnology or IntegrationTechnology transfer center providing expertise in biological/medical engineering and materials. Involved since early MailPan® development, contributing to biocompatible membrane performance improvements.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Defymed competitors and assessment

Company assessment

Broad incumbents

  • Insulet Corporation: Maker of the Omnipod 5 tubeless patch pump - the leading patch-style insulin delivery device on the market, competing for the same T1D patients and increasingly the benchmark for "wearable" insulin delivery that ExOlin must differentiate against.
  • Medtronic (Diabetes division): Dominant incumbent insulin pump maker (MiniMed 780G closed-loop system) serving the same T1D patient population that Defymed targets with ExOlin - represents both the competitive benchmark and the most likely strategic licensee for ExOlin post-CE marking.
  • Tandem Diabetes Care: Established insulin pump manufacturer (t:slim X2 with Control-IQ closed loop) competing directly with any future ExOlin launch in the T1D market, and a credible strategic acquirer/licensee candidate given its pure-play diabetes focus.

Direct peers

  • Sernova Corp: Develops the Cell Pouch System, an implantable cell-therapy delivery platform for islet cells in T1D and other therapeutic cells - conceptually adjacent to Defymed's MailPan bio-artificial pancreas, both targeting immune-protected cell therapy without chronic immunosuppression.
  • ViaCyte (acquired by Vertex Pharmaceuticals): Direct competitor developing PEC-Direct (VC-02) encapsulated stem-cell-derived pancreatic progenitor implants for Type 1 diabetes - same encapsulated cell-therapy-for-T1D concept as Defymed's MailPan. Acquired by Vertex in 2022, accelerating the competitive timeline.
  • Beta-O2 Technologies: Israeli company developing the βAir bio-artificial pancreas, an implantable macro-encapsulation device for allogeneic islet cells with oxygen supply - direct competing approach to Defymed's MailPan for T1D.

Emerging players

  • Procyon Technologies: Early-stage company developing an oxygen-generating cell-encapsulation platform for diabetes (similar therapeutic thesis to MailPan) - competitor for the same encapsulation-for-T1D thesis and for the same licensing partners.
  • Kadimastem: Israeli cell-therapy company developing IsletRx (insulin-secreting cells) - Defymed's named partner in the ENCAPSULIN project and a partial competitor since both pursue encapsulated cell therapy for T1D.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Defymed social profiles

Digital presence

Defymed compliance and trust

Trust signal

Compliance2 records

Defymed financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Defymed leadership team

Management profile

Number of profiles

Profiles7 records

Defymed funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Defymed M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Defymed

What does Defymed do?

Defymed develops and markets implantable bio-artificial medical devices for diverse therapeutic applications. Its two core products are MailPan®, a bio-artificial pancreas that encapsulates insulin-secreting cells within an immunoprotective semi-permeable membrane, and ExOlin®, a fully implantable insulin delivery device that enables physiological intraperitoneal insulin administration. Both are Class III soft-tissue implantable medical devices targeting type 1 diabetes and adjacent indications such as hemophilia, cancer therapy, and pain management.

Is Defymed a public or private company?

Defymed is a private company. It is classified as venture growth investor backed and is currently operating.

When was Defymed founded?

Defymed was founded in 2011. It employs 1 to 10 people.

Where is Defymed based?

Defymed is headquartered in Strasbourg, France, in the Europe region.

How does Defymed make money?

Two revenue lines are on record. Medical Device Licensing is the primary driver. The others are medical Device Development and Service Provision.

Who are Defymed's main competitors?

Broad incumbents on record are Insulet Corporation, Medtronic (Diabetes division) and Tandem Diabetes Care. Direct peers are Sernova Corp, ViaCyte (acquired by Vertex Pharmaceuticals) and Beta-O2 Technologies. Emerging players are Procyon Technologies and Kadimastem.

Does Defymed have an API?

No public API is recorded for Defymed.

What industry is Defymed in?

Defymed's product category is Implantable Medical Devices. Its primary akta.pro industry code is HLAHAIAG, Insulin Pumps & Patch Pumps, with a secondary code of HLAHAHAC, Patch Pumps & Wearable Insulin Delivery. Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireDefymed receives approval to start its pilot clinical study with ExOlin®: the promise of a physiological treatment for diabetic patientsDefymed, a French medical technology company, has received approval from French authorities to begin an open-label, single-centre pilot clinical study for the ExOlin\u00ae device at the University Hospitals of Strasbourg. The study will enroll 8 patients with poorly controlled type 1 diabetes experiencing severe glycaemic fluctuations and prone to severe hypoglycaemia, with initial results expected by the end of 2022. This first-in-human safety trial marks a key milestone in Defymed's 11-year development effort to provide a more physiological insulin delivery method, with plans to pursue CE marking and marketing approval by 2025.Business Wire BlogInnovative Medical Devices for the Treatment of Diabetes, Defymed Strengthens Its Position as a Worldwide LeaderDefymed, a French medtech firm, developed ExOlin, an insulin delivery device, and MailPan, a bioartificial pancreas for diabetes. The company plans to raise €10 million in 2018 to enter ExOlin into clinical trials and develop MailPan, seeking partnerships in Asia, Europe, and the USA.PR NewswireDefymed Receives Support from JDRF to Fight Type 1 DiabetesDefymed, a French biotechnology company, announced a partnership with JDRF, the leading global organization funding type 1 diabetes research, to advance pre-clinical studies for its MAILPAN® implantable bioartificial pancreas. The 24-month project will test the device's immunoprotection properties, safety, and functionality in combination with insulin-secreting cells, representing an essential step before beginning human clinical trials. This support provides Defymed with financial resources, U.S. market visibility, and strategic assistance as it prepares to enter the U.S. market while continuing its development in Europe.